{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:44:30Z","timestamp":1761630270343},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1054\/blre.2001.0145","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T14:55:24Z","timestamp":1032447324000},"page":"1-8","source":"Crossref","is-referenced-by-count":12,"title":["Oral antifungals as prophylaxis in haematological malignancy"],"prefix":"10.1054","volume":"15","author":[{"given":"A.G.","family":"Prentice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1054\/blre.2001.0145_RF1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3109\/02841869709001316","article-title":"Allogeneic bone marrow transplantation for hematological malignancies \u2013 controversies and recent advances [review]","volume":"36","author":"Ringd\u00e9n","year":"1997","journal-title":"Acta Oncol"},{"key":"10.1054\/blre.2001.0145_RF2","first-page":"635","article-title":"Variables predicting deep fungal infections in bone marrow transplant recipients","volume":"4","author":"Tollemar","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1054\/blre.2001.0145_RF3","first-page":"10","article-title":"Fungal infections in bone marrow transplant patients","volume":"17 (Suppl 6)","author":"Meyers","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1054\/blre.2001.0145_RF4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF6","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation \u2013 a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/BF01690991","article-title":"An autopsy study of systemic fungal infections in patients with hematologic malignancies","volume":"14","author":"Jandrlic","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-91-4-539","article-title":"Candida tropicalis: a major pathogen in immunocompromised patients","volume":"91","author":"Wingard","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1054\/blre.2001.0145_RF9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/clinids\/20.1.115","article-title":"Importance of Candida species other than C. albicans","volume":"20","author":"Wingard","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF10","first-page":"175","article-title":"Aspergillus infections in bone marrow transplant recipients","volume":"2","author":"Wingard","year":"1987","journal-title":"Bone Marrow Transplant"},{"key":"10.1054\/blre.2001.0145_RF11","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/40.6.779","volume":"40","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/blre.2001.0145_RF12","first-page":"63","article-title":"Systemic fungal infection in haematological malignancy \u2013 current therapy","volume":"5","author":"Prentice","year":"1997","journal-title":"Curr Med Lit Leukemia Lymphoma"},{"key":"10.1054\/blre.2001.0145_RF13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","volume":"86","year":"1989","journal-title":"Am J Med"},{"key":"10.1054\/blre.2001.0145_RF14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1054\/blre.2001.0145_RF15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1054\/blre.2001.0145_RF16","first-page":"S111","article-title":"Itraconazole (IT) compared with amphotericin B (AMB) as empirical therapy for persistent fever of unknown origin (FUO) in neutropenic patients (PTS)","volume":"23 (Suppl 1)","author":"Boogaerts","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1054\/blre.2001.0145_RF17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1054\/blre.2001.0145_RF18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1439-0507.1996.tb00149.x","article-title":"Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk","volume":"39","author":"Schafer-Korting","year":"1996","journal-title":"Mycoses"},{"key":"10.1054\/blre.2001.0145_RF20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0030-4220(84)90128-2","article-title":"Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients","volume":"58","author":"Barrett","year":"1984","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1054\/blre.2001.0145_RF21","first-page":"139","article-title":"Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome","volume":"8","author":"Buchanan","year":"1985","journal-title":"Clin Invest Med"},{"key":"10.1054\/blre.2001.0145_RF22","first-page":"S94","article-title":"Ketoconazole vs","volume":"9 (Suppl 1)","author":"Tricot","year":"1987","journal-title":"itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-198308010-00002","article-title":"Clinical pharmacokinetics of systemic antifungal drugs","volume":"8","author":"Daneshmend","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"10.1054\/blre.2001.0145_RF24","first-page":"539","article-title":"Antifungal agents in the 1990s","volume":"53","author":"Kauffman","year":"1997","journal-title":"Current status and future developments. Drugs"},{"key":"10.1054\/blre.2001.0145_RF25","first-page":"263","article-title":"Oral azole drugs as systemic antifungal therapy","volume":"330","author":"Como","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1054\/blre.2001.0145_RF26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1378\/chest.110.2.525","article-title":"New antifungal drugs for pulmonary mycoses","volume":"110","author":"Klein","year":"1996","journal-title":"Chest"},{"key":"10.1054\/blre.2001.0145_RF27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF02017693","article-title":"Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy","volume":"5","author":"Stockley","year":"1986","journal-title":"Eur J Clin Microbiol"},{"key":"10.1054\/blre.2001.0145_RF28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(89)91802-3","article-title":"Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients","volume":"ii","author":"First","year":"1989","journal-title":"Lancet"},{"key":"10.1054\/blre.2001.0145_RF29","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/archinte.1983.00350090184035","article-title":"Successful ketoconazole treatment of protothecosis with ketoconazole-associated hepatotoxicity","volume":"143","author":"Pegram","year":"1983","journal-title":"Arch Intern Med"},{"key":"10.1054\/blre.2001.0145_RF30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ddr.430080133","article-title":"Cytochrome P450: target for itraconazole","volume":"8","author":"Vanden Bossche","year":"1986","journal-title":"Drug Dev Res"},{"key":"10.1054\/blre.2001.0145_RF31","first-page":"74","article-title":"Fluconazole and itraconazole: current status and prospects for antifungal therapy [review]","volume":"13","author":"Sugar","year":"1993","journal-title":"Curr Clin Top Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF32","article-title":"Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial","author":"Studena","year":"1995","journal-title":"J Chemother"},{"key":"10.1054\/blre.2001.0145_RF33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/infdis\/172.4.1035","article-title":"Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias","volume":"172","author":"Schaffner","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF34","first-page":"495","article-title":"Fluconazole prophylaxis of fungal infections in patients with acute leukemia","volume":"118","author":"Winston","year":"1993","journal-title":"Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med"},{"key":"10.1054\/blre.2001.0145_RF35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/AAC.30.3.418","article-title":"Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo","volume":"30","author":"Rogers","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/blre.2001.0145_RF36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/infdis\/170.2.384","article-title":"Correlation between in vitro and in vivo activity of antifungal agents against Candida species","volume":"170","author":"Anaissie","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF37","first-page":"235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections","volume":"24","author":"Rex","year":"1997","journal-title":"Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF38","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1054\/blre.2001.0145_RF39","first-page":"543","article-title":"Opportunistic mycoses in the immunocompromised host: experience at a cancer centre and review","volume":"14 (Suppl 1)","author":"Anaissie","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/31.6.973","article-title":"Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia","volume":"31","author":"Philpott-Howard","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/blre.2001.0145_RF41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1054\/blre.2001.0145_RF42","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-120-11-199406010-00003","article-title":"the GIMEMA Infection Program Preventing fungal infection in neutropenic patients with acute leukaemia: fluconazole compared with oral amphotericinB","volume":"120","author":"Menichetti","year":"1994","journal-title":"Annals of Internal Medicine"},{"key":"10.1054\/blre.2001.0145_RF43","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.37.9.1962","article-title":"Fluconazole resistance in Candida glabrata","volume":"37","author":"Hitchcock","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/blre.2001.0145_RF44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3949\/ccjm.64.2.99","article-title":"The role of azole antifungal agents for systemic antifungal therapy","volume":"64","author":"Lee","year":"1997","journal-title":"Cleve Clin J Med"},{"key":"10.1054\/blre.2001.0145_RF45","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1054\/blre.2001.0145_RF46","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/clinids\/19.Supplement_1.S49","article-title":"Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy","volume":"19 (Suppl 1)","author":"Wingard","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF47","first-page":"23","article-title":"Pharmacokinetic optimization of the treatment of oral candidiasis with fluconazole: studies with a suspension","volume":"21","author":"Laufen","year":"1995","journal-title":"Drugs Exp Clin Res"},{"key":"10.1054\/blre.2001.0145_RF48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199325040-00006","article-title":"Pharmacokinetic optimisation of oral antifungal therapy","volume":"25","author":"Schafer-Korting","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1054\/blre.2001.0145_RF49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0190-9622(99)70055-1","article-title":"Drug interactions with itraconazole, fluconazole, and terbinafine and their management","volume":"41","author":"Gupta","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1054\/blre.2001.0145_RF50","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/clinids\/9.Supplement_1.S71","article-title":"Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results","volume":"9 (Suppl 1)","author":"Dupont","year":"1987","journal-title":"Rev Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF51","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/clinids\/9.Supplement_1.S15","article-title":"Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models [review]","volume":"9 (Suppl 1)","author":"Van Cutsem","year":"1987","journal-title":"Rev Infect Dis"},{"key":"10.1054\/blre.2001.0145_RF52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effect of the food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Van Peer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1054\/blre.2001.0145_RF53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32 (Suppl 1)","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"key":"10.1054\/blre.2001.0145_RF54","first-page":"502","article-title":"Example of active therapeutic follow-up: itraconazole","volume":"51","author":"Levron","year":"1996","journal-title":"Therapie"},{"key":"10.1054\/blre.2001.0145_RF55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s002280050438","article-title":"Effect of omeprazole on the pharmacokinetics of itraconazole","volume":"54","author":"Jaruratanasirikul","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1054\/blre.2001.0145_RF56","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/0959-8049(92)90127-N","article-title":"Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment","author":"Persat","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1054\/blre.2001.0145_RF57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1054\/blre.2001.0145_RF58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","article-title":"Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole","volume":"16","author":"Van de Velde","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1054\/blre.2001.0145_RF59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/34.2.247","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients","volume":"34","author":"Prentice","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/blre.2001.0145_RF60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/36.4.657","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia","volume":"36","author":"Prentice","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1054\/blre.2001.0145_RF61","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V88.9.3662.bloodjournal8893662","article-title":"Itraconazole more bioavailable in solution [letter]","volume":"88","author":"Prentice","year":"1996","journal-title":"Blood"},{"key":"10.1054\/blre.2001.0145_RF62","first-page":"3205","article-title":"Lack of interaction of antacid drug omeprazole on the bioavailability of itraconazole oral solution","volume":"92 (Suppl 1)","author":"Levron","year":"1998","journal-title":"Blood"},{"key":"10.1054\/blre.2001.0145_RF63","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.bmt.1701270","article-title":"Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation","volume":"21","author":"Michallet","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1054\/blre.2001.0145_RF64","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1702023","article-title":"Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders","volume":"24","author":"Foot","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1054\/blre.2001.0145_RF65","first-page":"68a","article-title":"Intravenous itraconazole can replace oral solution in Aspergillus prophylaxis: pharmacokinetic data from patients treated for haematological malignancies","volume":"108 (Suppl. 1)","author":"Prentice","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1054\/blre.2001.0145_RF66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1439-0507.1996.tb00514.x","article-title":"Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis [in German]","volume":"39 (Suppl 1)","author":"Eichel","year":"1996","journal-title":"Mycoses"},{"key":"10.1054\/blre.2001.0145_RF67","article-title":"Itraconazole oral solution for the treatment of fluconazole-refractory oropharyngeal candidiasis in HIV-positive patients [abstract 327]","author":"Fessel","year":"1997","journal-title":"4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, USA,"},{"key":"10.1054\/blre.2001.0145_RF68","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-199610000-00009","article-title":"Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility","volume":"10","author":"Phillips","year":"1996","journal-title":"AIDS"},{"key":"10.1054\/blre.2001.0145_RF69","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B","volume":"44","author":"Harousseau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1054\/blre.2001.0145_RF70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(87)90873-7","article-title":"Interaction of cyclosporin and itraconazole","volume":"ii","author":"Kwan","year":"1987","journal-title":"Lancet"},{"key":"10.1054\/blre.2001.0145_RF71","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/S0041-1345(97)00546-0","article-title":"Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK506)","volume":"29","author":"Kramer","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1054\/blre.2001.0145_RF72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00007691-199808000-00007","article-title":"Effect of metabolic inhibitors on cyclosporin pharmacokinetics using a population approach","volume":"20","author":"McLachlan","year":"1998","journal-title":"Therapy Drug Monitoring"},{"key":"10.1054\/blre.2001.0145_RF73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF01697985","article-title":"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL","volume":"71","author":"B\u00f6hme","year":"1995","journal-title":"Ann Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X01901456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X01901456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T22:34:17Z","timestamp":1704321257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X01901456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["S0268960X01901456"],"URL":"https:\/\/doi.org\/10.1054\/blre.2001.0145","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}